Goal 3: Advance Translational Research

To facilitate innovation and accelerate research translation, knowledge dissemination, and implementation science that enhances public health.

Goal 3: Advance Translational Research

Submitted by (@nhlbiforumadministrator)

Inhaled antibiotics for patients with bronchiectasis

Many pharma companies are developing inhaled antibiotics for patients with bronchiectasis, recognizing the increasing market (over 110,000 patients in the US). These drugs cost thousands of dollars per year and will be heavily marketed and heavily used, as there are limited options for these patients. It is unknown if rotating oral antibiotics (cost is a fraction of the inhaled ABx) would yield similar results.  A Cochrane ...more »

Voting

1 net vote
1 up votes
0 down votes
Active

Goal 3: Advance Translational Research

Submitted by (@nhlbiforumadministrator)

Harnessing the ongoing ‘natural experiments’ of quality improvement

How do we harness the ongoing “natural experiments” of quality improvement (QI) activities in various healthcare systems to facilitate hypothesis-driven research, improve scientific validity to address questions in clinical trials, and implement and disseminate research results? • Current restrictions in human subjects research regulations • Diversity in approaches and methodology rigor to QI initiatives across different ...more »

Voting

-2 net votes
11 up votes
13 down votes
Active

Goal 3: Advance Translational Research

Submitted by (@giralts)

Can we leverage exisiting registries to perform prospective trials and advance reduce the cost of doing research?

Current costs for multicenter randomized or non randomized trials are astronomical, and a major obstacle to rapid implementation of potential lifesaving discoveries. In the field of hematopoietic cell transplantation (HCT) their is a federal mandate to have a treatment outcome registry. Funds should be made available to leverage that registry to perform prospective trials either randomized or not since HCT programs need ...more »

Voting

123 net votes
154 up votes
31 down votes
Active

Goal 3: Advance Translational Research

Submitted by (@nhlbiforumadministrator)

Bone Marrow Stem Cell Transplant in Peds sibling matched SCD

There is a need to improve accessibility of Bone Marrow Stem Cell Transplantation (BMSCT) for Sickle Cell Disease patients who are most likely to benefit from this treatment option. 1. Building a culture of trust between and among primary care providers, specialists, patients/families, and other stakeholders 2. Consensus building around BMSCT as an acceptable treatment alternative (as opposed to another research endeavor) ...more »

Voting

52 net votes
80 up votes
28 down votes
Active

Goal 3: Advance Translational Research

Submitted by (@nhlbiforumadministrator)

Advancing the science of translating evidence into practice

What are the best ways for the NHLBI to advance the evolving science of translating robust evidence into clinical practice domestically and globally? How to personalize broad research evidence for individual patients? How to predict and evaluate the impact of evidence-based interventions? How to identify implementation methods available in industry and elsewhere that work best and are most translatable in healthcare? ...more »

Voting

13 net votes
27 up votes
14 down votes
Active

Goal 3: Advance Translational Research

Submitted by (@rwise0)

Novel Treatments for COPD

COPD is a major health problem leading to 140,000 deaths in the United States. Treatments are supportive, but there is a compelling need for treatments that modify the progression of the disease and that prevent exacerbations. There needs to be a research infrastructure that unites basic, translational, and clinical researchers to develop new approaches. Although this challenge had been met in the past with the now ...more »

Voting

16 net votes
23 up votes
7 down votes
Active

Goal 3: Advance Translational Research

Submitted by (@nhlbiforumadministrator)

Achieving Transplantation Tolerance in Recipients of Heart and Lung Allografts

Despite improvements in the early post-transplant survival of thoracic organs, registry data show that the graft half-life is only 11 years for heart recipients and 5 years for lung recipients. Infection accounts for 33% of cardiac and 40% of lung transplant recipient death between day 31 and one year post transplant. After 5 years, cardiac allograft vasculopathy (30%), and malignancy (23%) cause most cardiac recipient ...more »

Voting

7 net votes
24 up votes
17 down votes
Active